Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health's recent strategic transaction is seen as a significant move to refocus the company on its drug development capabilities while simultaneously strengthening its balance sheet. The company reported a cash-rich position and noted improvements in productivity at BioReference, which aims for profitability by 2025 through cost reductions and innovation in specialty testing. Additionally, OPKO's fourth-quarter revenue of $183.6 million, representing a slight year-over-year increase, surpassed projections, demonstrating resilience and effective management of its operations.

Bears say

OPKO Health Inc. reported a significant decline in revenue across its segments, with diagnostics services revenue decreasing by 17% year-over-year to $103.1 million and total revenue for the full year 2024 also reflecting a 17% year-over-year decline at $713.1 million. The pharmaceutical products revenue experienced a 13% decline, totaling $37.4 million, largely attributed to unfavorable foreign currency exchange impacts. Overall, the company faces multiple risks, including lower-than-anticipated growth in diagnostics services, challenges in developing and securing regulatory approval for new pharmaceuticals, and sales fluctuations linked to emerging markets and currency exchange rates, which contribute to the negative outlook on its stock.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.